Carregando...
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
INTRODUCTION: Lenalidomide is an active agent that was approved for use in the EU in 2015 as a first-line therapy for previously untreated, non-transplant eligible multiple myeloma patients. Our objective was to assess the cost impact of lenalidomide when selected as a first-line treatment for trans...
Na minha lista:
| Publicado no: | Oncol Ther |
|---|---|
| Principais autores: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488111/ https://ncbi.nlm.nih.gov/pubmed/28680953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-016-0037-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|